Genome Atlantic launches Small-Scale Climate Change Fund

applications are now closed

Atlantic Canada faces unique and difficult challenges as climate change progresses. This targeted funding opportunity is intended to support short term, rapid initiatives which will advance identification, development and/or adoption of genomics tools that lead to solutions that help to combat climate change.

The goal for this program is to provide a foundation for Atlantic Canadian stakeholders to pursue subsequent larger scale Climate Change funding initiatives, such as Genome Canada’s anticipated flagship mission.

The Small-Scale Climate Change Fund is led by Genome Atlantic, in partnership with Research Nova Scotia.

Download the application form (NOW CLOSED) for more information on topic eligibility. If you are unsure if your proposed project is a fit, please reach out with questions to the address below.

Please note:
• Project contributions can range from $5,000 to $20,000
• Applications are due February 14th, 2022
• Projects must be completed or at least be able to demonstrate preliminary results by May 31st, 2022

For more information or to apply, please contact Kristin Tweel (

Atlantic Business Magazine Feature

Genome Atlantic: Writing the code for regional innovation and commercial success

In a region the rest of the world often appreciates only for its coastal vistas and pastoral beauty, the virtuous marriage of hard science and bold business is transforming the way people live and work, one extraordinary innovation at a time.

This is Genome Atlantic, a not-for-profit corporation with a mission to help Atlantic Canada reap the economic and social benefits of genomics and associated technologies in everything from agriculture, fisheries and aquaculture to energy, the environment, forestry, mining, and human health.

Says Steve Armstrong, Genome Atlantic’s President and CEO: “Delivering meaningful socio-economic impact requires innovation-friendly companies, creative academic experts, and a mix of private and public sector investment. That means exploring opportunities, finding partners and developing proposals. We are the connective tissue that has been bringing those key success factors together for 21 years.”

Since its inception in 2000, Genome Atlantic has been instrumental in putting together approximately $150 million in client-led projects focused on delivering tangible economic and health benefits. Now, says Armstrong, the region’s demand for genomics-based solutions has never been greater.

“Increasingly DNA-based or genomic technologies are an essential element of the innovation toolkit for companies and select public sector entities spanning just about any sector you can imagine,” he notes. “Many companies simply will not remain competitive if they do not continue – or in some cases, start – using genomics technologies. From optimizing agri-food and aquaculture production, to growing trees with the desired traits, to effectively monitoring their environmental footprint, to adapting to climate change: Genomics is key to all of that.”

The numbers are, indeed, convincing. Over the past five years alone, Genome Atlantic has seen a three-fold growth in R&D investment, almost all driven by end-user need and much of that from the private sector. In fact, business expenditure on R&D (BERD) represents about 25 per cent of the corporation’s project portfolio, compared with eight per cent in 2008. That portfolio consists of 23 current active projects valued at close to $60 million, in partnership with 25 companies and 15 universities.